| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 09/18/2007 | CA2095797C Arylacetamides |
| 09/18/2007 | CA2032859C Method of reducing or preventing adverse effect of steroid therapy and compositions therefor |
| 09/16/2007 | CA2581960A1 Iap bir domain binding compounds |
| 09/13/2007 | WO2007104053A2 8-heteroarylpurine mnk2 inhibitors for treating metabolic disorders |
| 09/13/2007 | WO2007104035A1 Modulation of neurogenesis by nootropic agents |
| 09/13/2007 | WO2007104034A2 Glucokinase activators |
| 09/13/2007 | WO2007104030A1 Retinoids and related compounds for the treatment of neuroinflammatory conditions, diseases and disorders |
| 09/13/2007 | WO2007103996A1 2-(aryloxy)acetamide factor viia inhibitors useful as anticoagulants |
| 09/13/2007 | WO2007103970A2 Compositions and methods for treating respiratory disorders |
| 09/13/2007 | WO2007103934A2 Compositions and methods of use of ritonavir for treating hcv |
| 09/13/2007 | WO2007103931A2 Nanofluidized b-12 composition and process for treating pernicious anemia |
| 09/13/2007 | WO2007103905A2 Prolyl hydroxylase inhibitors |
| 09/13/2007 | WO2007103884A2 Compositions and methods for the treatment of multiple sclerosis |
| 09/13/2007 | WO2007103828A2 Fluorocytidine derivatives and cox-2 inhibitors for the treatment of cancer |
| 09/13/2007 | WO2007103816A2 Polymorphisms in voltage-gated sodium channel alpha 1-subunit as markers for therapy selection |
| 09/13/2007 | WO2007103814A2 Angiogenesis pathway gene polymorphisms for therapy selection |
| 09/13/2007 | WO2007103782A2 Pharmaceutical latrunculin formulations |
| 09/13/2007 | WO2007103762A2 Compositions and methods of use of electron transport system inhibitors |
| 09/13/2007 | WO2007103760A2 Thiazolones for use as pi3 kinase inhibitors |
| 09/13/2007 | WO2007103759A2 Thiazolones for use as pi3 kinase inhibitors |
| 09/13/2007 | WO2007103758A2 Thiazolones for use as pi3 kinase inhibitors |
| 09/13/2007 | WO2007103756A2 Thiazolones for use as pi3 kinase inhibitors |
| 09/13/2007 | WO2007103755A2 Thiazolones for use as pi3 kinase inhibitors |
| 09/13/2007 | WO2007103754A2 Thiazolones for use as pi3 kinase inhibitors |
| 09/13/2007 | WO2007103719A2 MODULATORS OF 11-β HYDROXYL STEROID DEHYDROGENASE TYPE 1, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USING THE SAME |
| 09/13/2007 | WO2007103711A2 Polymorphic forms of rimonabant |
| 09/13/2007 | WO2007103683A2 Compounds for inhibiting beta-amyloid production |
| 09/13/2007 | WO2007103670A2 Novel compounds that are useful for improving pharmacokinetics |
| 09/13/2007 | WO2007103665A2 Polyfunctional compounds and uses as implant materials |
| 09/13/2007 | WO2007103638A2 Hormone replacement formulation |
| 09/13/2007 | WO2007103584A2 Polyamides for treating human papilloma virus |
| 09/13/2007 | WO2007103557A2 Coating capsules with active pharmaceutical ingredients |
| 09/13/2007 | WO2007103554A1 Quinoline and isoquinoline derivatives as phosphodiesterase 10 inhibitors |
| 09/13/2007 | WO2007103549A2 Complement binding aptamers and anti-c5 agents useful in the treatment of ocular disorders |
| 09/13/2007 | WO2007103534A2 Ethyl nitrite as a gastrointestinal smooth muscle relaxant and diagnostic and therapeutic uses thereof |
| 09/13/2007 | WO2007103528A2 Compressible resilient granules and formulations prepared therefrom |
| 09/13/2007 | WO2007103510A2 Methods, dosing regimens & medications using anti-progestational agents for the treatment of disorders |
| 09/13/2007 | WO2007103508A2 Ligands for nematode nuclear receptors and uses thereof |
| 09/13/2007 | WO2007103491A2 Construction imaging and archiving method, system and program |
| 09/13/2007 | WO2007103453A1 Ezetimibe compositions |
| 09/13/2007 | WO2007103447A2 A method for the preparation of recombinant human thrombin |
| 09/13/2007 | WO2007103427A2 Medical use of bilirubin and its structural analogues |
| 09/13/2007 | WO2007103378A2 Composition for hands |
| 09/13/2007 | WO2007103373A2 Compositions and methods for the treatment of immunoinflammatory disorders |
| 09/13/2007 | WO2007103366A2 Hmg co-a reductase inhibitor enhancement of bone and cartilage |
| 09/13/2007 | WO2007103347A1 Meridamycin analogues for the treatment of neurodegenerative disorders |
| 09/13/2007 | WO2007103341A2 Composition for enhancing muscle mass development in animals |
| 09/13/2007 | WO2007103295A2 Halogenated sulfonamide derivatives |
| 09/13/2007 | WO2007103273A2 Thioredoxin and thioredoxin reductase inhibitors |
| 09/13/2007 | WO2007103260A1 Phosphodiesterase 10 inhibitors |
| 09/13/2007 | WO2007103252A2 Novel crystalline forms of antidiabetic compounds |
| 09/13/2007 | WO2007103221A2 An improved process for the preparation of armodafinil |
| 09/13/2007 | WO2007103190A2 Transdermal treatment of tendinop athy using no donor |
| 09/13/2007 | WO2007103185A2 Sustained release dosage forms of analagesic medications |
| 09/13/2007 | WO2007103162A2 Structure based drug design of steroidogenesis inhibitors |
| 09/13/2007 | WO2007103160A2 Stearidonic acid for improving cardiovascular health |
| 09/13/2007 | WO2007103149A2 Treatment of atherosclerotic disease |
| 09/13/2007 | WO2007103132A2 Method and apparatus for acne treatment using low intensity light therapy |
| 09/13/2007 | WO2007103111A2 Antiviral drugs for treatment of arenavirus infection |
| 09/13/2007 | WO2007102888A2 Methods of treating cancer with doxazolidine and prodrugs thereof |
| 09/13/2007 | WO2007102883A2 Chemical compounds |
| 09/13/2007 | WO2007102771A1 Phenethanolamine derivatives as beta2 adrenoreceptor agonists |
| 09/13/2007 | WO2007102770A1 Gsk-3 inhibitors for the treatment of osteoporosis |
| 09/13/2007 | WO2007102769A2 Piperidine derivatives, their process for preparation, their use as therapeutic agents and pharmaceutical compositions containing them |
| 09/13/2007 | WO2007102768A1 Piperidine derivatives, their process for preparation, their use as therapeutic agents and pharmaceutical compositions containing them . |
| 09/13/2007 | WO2007102767A1 Piperidine derivatives, their process for preparation, their use as therapeutic agents and pharmaceutical compositions containing them |
| 09/13/2007 | WO2007102726A1 Synergic combination of h2-receptor inhibitors, inert silicone and a hydroxymagnesium aluminate complex |
| 09/13/2007 | WO2007102725A1 Synergic combination of l-type calcium-channel blockers with selective action in respect of the gastrointestinal tract and an inert silicone |
| 09/13/2007 | WO2007102703A1 Composition for prevention or treatment of diseases in central nervous system comprising extract of cimicifuga heracleifolia komarow |
| 09/13/2007 | WO2007102660A1 Vanilloid receptor antagonist for prevention and treatment of drug dependence and addiction |
| 09/13/2007 | WO2007102608A1 Stabilizer for hydrophobic compounds |
| 09/13/2007 | WO2007102580A1 Polycyclic cinnamide derivative |
| 09/13/2007 | WO2007102572A1 Inhibitor for cellular aging |
| 09/13/2007 | WO2007102571A1 Therapeutic agent for functional brain disease |
| 09/13/2007 | WO2007102531A1 Pharmaceutical combination |
| 09/13/2007 | WO2007102515A1 Phenylthiazole derivative |
| 09/13/2007 | WO2007102467A1 Aqueous solution of conophylline and/or conophyllidine |
| 09/13/2007 | WO2007102451A1 Hair grower |
| 09/13/2007 | WO2007102447A1 Adhesive microcapsule |
| 09/13/2007 | WO2007102439A1 Fractionation product of aqueous extract of eucommia ulmoides oliver leaf, and composition for oral ingestion comprising the fractionation product |
| 09/13/2007 | WO2007102438A1 Fractionation product of aqueous extract of eucommia ulmoides oliver leaf, and anti-obesity agent comprising the fractionation product |
| 09/13/2007 | WO2007102392A1 Mmp-13-selective inhibitor |
| 09/13/2007 | WO2007102368A1 Novel 3-(1-aminoalkylidene)furan-2,4(3h,5h)-dione derivative, method for producing the same, and pharmaceutical composition containing the same as active ingredient |
| 09/13/2007 | WO2007102326A1 Strong immune induction by using combination of adenovirus type-5/type-35 vector and vaccinia virus mva vector |
| 09/13/2007 | WO2007102243A1 External pharmaceutical composition |
| 09/13/2007 | WO2007102242A1 External pharmaceutical composition |
| 09/13/2007 | WO2007102241A1 External pharmaceutical composition |
| 09/13/2007 | WO2007102169A1 Extended release pharmaceutical formulation of venlafaxine and method of manufacturing the same |
| 09/13/2007 | WO2007102149A2 Hydrazido derivatives of hyaluronic acid |
| 09/13/2007 | WO2007102082A1 High oxazolidinone content solid dosage forms |
| 09/13/2007 | WO2007102069A1 Improved prodrugs of cc-1065 analogs |
| 09/13/2007 | WO2007102061A2 Prodrugs of benzoquinolizine-2-carboxylic acid |
| 09/13/2007 | WO2007102058A1 Alpha-2-delta ligands for non-restorative sleep |
| 09/13/2007 | WO2007102038A1 Ziprasidone formulations |
| 09/13/2007 | WO2007102019A1 The use of bupropion metabolites for the treatment of inflammatory disorders |
| 09/13/2007 | WO2007102011A1 The use of beta-aminoalcohols for the treatment of inflammatory disorders and pain |
| 09/13/2007 | WO2007102008A1 The use of beta-aminoalcohols in the treatment of inflammatory disorders and pain |
| 09/13/2007 | WO2007101937A1 Composition containing amidine derivatives or carboxamide derivatives and steroids, as a medicament |
| 09/13/2007 | WO2007101935A2 Novel heterocyclic cycloalkyl derivatives, method for the preparation thereof, and pharmaceutical compositions containing the same |
| 09/13/2007 | WO2007101925A1 Use of 3,5-seco-4-norcholestane derivatives for obtaining a cytoprotective medicament |